With Elon Musk clearly outlining a mass production timeline for brain-computer interface (BCI) devices, this cutting-edge field is accelerating its transition from scientific exploration in the laboratory to commercial application, potentially reaching a critical turning point from "medical experimental product" to "mass-market consumer good."
On the first trading day of 2026 for A-shares, the BCI sector performed strongly. Beiyikang surged by the 30% daily limit, while Sanbo Brain Science, Xiangyu Medical, Meihao Medical, Aipeng Medical, Chengyitong, Weisi Medical, and several other stocks hit the 20% daily limit, demonstrating the market's extremely high expectations for the commercial prospects of BCI.
The direct trigger for this market surge was the latest developments from Neuralink. On January 1st local time, Musk announced on social media that Neuralink will commence mass production of its BCI device in 2026 and advance a surgical solution that is almost entirely automated. Simultaneously, Merge Labs, backed by OpenAI CEO Sam Altman, is spinning off as an independent entity to focus on a new technological approach using ultrasound to read brain activity. The moves by these two tech giants indicate that BCI is evolving from a singular scientific experiment into a diversified commercial race.
These series of advancements not only validate the feasibility of the technology but have also prompted a market reassessment of BCI's vast application potential in areas such as medical rehabilitation, AI interconnection, and collaboration with humanoid robots. Multiple brokerages have pointed out that, driven by both technological breakthroughs and increased policy support, the industry is in a period of high-growth momentum accumulation. Investors are advised to closely monitor leading companies with core technologies and compliance barriers, as well as the genuine market demand that can separate the "wheat from the chaff."
The expectation of mass production and a major overhaul of the surgical solution are key milestones. Kaiyuan Securities noted in its latest research report that Neuralink's mass production expectations and automated surgical plan hold dual milestone significance. This not only marks BCI's transition from a "medical testing tool" to a "popularizable product" but also lays the foundation for future synergistic applications with Tesla's Optimus humanoid robot. Neuralink's technological evolution path is now quite clear. Currently, 12 people globally have been implanted with the Neuralink device, accumulating over 15,000 hours of usage time; the first recipient, Noland Arbaugh, can already type and play games using his mind. According to Neuralink's plan, the number of electrode channels will increase to 3,000 by 2026, accompanied by clinical tests for artificial vision; the target for 2028 is over 25,000 electrode channels per device, achieving full-brain region connectivity.
A report from Morgan Stanley's analysis team, led by Adam Jonas, indicates that Neuralink's current valuation is approximately $9 billion, with its commercialization process significantly accelerating. The report predicts that in the US market alone, the total potential market size for BCI implant devices could reach $80 billion by 2035, primarily covering treatments for neurological diseases like ALS and stroke.
The global BCI field is fiercely competitive, exhibiting a differentiated technological landscape. In terms of clinical progress and regulatory approvals, both China and the US are in the clinical trial stage for invasive technologies, with the US progressing faster in semi-invasive areas, while China shows a flourishing diversity of approaches in the non-invasive domain.
Domestic Chinese companies have made significant progress in specific areas. Brain Tiger Technology, a domestic invasive BCI company, has independently developed a 256-channel high-throughput implantable flexible BCI, signifying that China has reached world-leading levels in this field. In the non-invasive sector, BrainCo has launched a consumer-facing smart sleep aid device, while companies like Chengyitong and Xiangyu Medical plan to apply the technology to anesthesia monitoring and medical rehabilitation.
CSC Financial believes that there is no inherent superiority or inferiority between non-invasive and invasive BCI; the key lies in identifying "true BCI" applications that have both national policy support and genuine market demand. China's BCI technology research progress is relatively advanced globally, and its manufacturing supply chain advantages are prominent, holding the potential to cultivate world-leading BCI enterprises.
Beyond essential medical needs, BCI is seen as the key to unlocking the ultimate form of human-machine collaboration. Kaiyuan Securities analysis suggests the BCI industry is expanding from essential medical applications into diverse fields like AI and robotics. Musk has explicitly stated that future upgrades to Neuralink technology could enable remote control of Optimus robots via thought, building an ultimate ecosystem of "human brain + robot."
According to data from Precedence Research, the global BCI market size is expected to grow to approximately $12.4 billion by 2034, with a compound annual growth rate of 17% from 2025 to 2034. Morgan Stanley goes further, predicting the market size could leap to $320 billion by 2045.
CSC Financial points out that BCI represents both a medical and a technology investment. In the short term, motor decoding products are expected to commercialize first in rehabilitation for conditions like paralysis and ALS. In the long term, if capabilities for human enhancement and fusion with AI and robots are achieved, it could unlock a market space worth trillions of dollars.
Ongoing policy support provides a solid foundation for the industry's development. BCI has been explicitly designated as a future industry for layout in China's "15th Five-Year Plan." A 2025 implementation opinion set targets for core technology breakthroughs by 2027 and for industrial strength to rank among the world's forefront by 2030. Furthermore, the National Healthcare Security Administration has issued documents requiring the proper coding and declaration of innovative medical consumables like BCI, solving the "last mile" problem for product adoption in hospitals. The industry standard "Medical Device Terminology for Devices Using Brain-Computer Interface Technology," released by the National Medical Products Administration, is also set to take effect in 2026.
Tianfeng Securities recommends that investors focus on companies forming a closed loop integrating "policy + device + algorithm + clinical application," as well as leading companies with advantages in device R&D and algorithm optimization. Attention should also be paid to the development of regional industrial clusters, such as Guangdong Province, which hosts a large number of BCI companies, and Beijing, which leads in patent applications.
In the long run, leading enterprises will establish dual barriers of technology and regulatory compliance. CSC Financial suggests focusing on companies with core patents, leading R&D capabilities, and adherence to strict medical regulations, as well as those traditional businesses that can leverage their existing resources to accelerate the development of their BCI operations.